Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial

Peripheral Histamine 1 Receptor Blockade in IBS

Purpose:

To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine.

Design:

Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).

Inclusion Criteria:

• Irritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed form
• age 18-65 years

Exclusion Criteria:

• IBS subtype with constipation
• medication: antidepressants or H1-receptor antagonists
• pregnancy, breast feeding
• co-morbidity: severe kidney- and/or liver disease or other gastrointestinal diseases